Literature DB >> 26038816

The G1 phase E3 ubiquitin ligase TRUSS that gets deregulated in human cancers is a novel substrate of the S-phase E3 ubiquitin ligase Skp2.

Azfar Jamal1, Manickavinayaham Swarnalatha, Sarwat Sultana, Prashant Joshi, Subrat K Panda, Vijay Kumar.   

Abstract

E3 ubiquitin ligases have been implicated in the ubiquitination and proteasome-mediated degradation of several key regulators of cell cycle. Owing to their pleotropic behavior, E3 ubiquitin ligases are tightly regulated both at transcriptional and post-translational levels. The E3 ubiquitin ligase TRUSS (tumor necrosis factor receptor-associated ubiquitous scaffolding and signaling protein) which negatively regulates c-Myc, are found down-regulated in most human cancer cell lines. However, the mechanism of regulation of intracellular levels of TRUSS remains elusive. Here we show that TRUSS is expressed majorly during the G1 phase of cell cycle and its level starts to decline with the expression of S-phase specific E3 ligase Skp2. Enforced expression of Skp2 led to a marked increase in the ubiquitination of TRUSS after its phosphorylation by GSK3β and followed by rapid proteolytic degradation. Our co-immunoprecipitation studies suggested a direct interaction between Skp2 and TRUSS through the LRR motif of Skp2. Interestingly, the human tumor samples that exhibited elevated expression of Skp2, showed relatively poor expression of TRUSS. Further, enforced expression of HBx, the oncoprotein of Hepatitis B virus which is known to stabilize c-Myc and enhance its oncogenic potential, led to the intracellular accumulation of TRUSS as well as c-Myc. Apparently, HBx also interacted with TRUSS which negatively impacted the TRUSS-c-Myc and TRUSS-Skp2 interactions leading to stabilization of TRUSS. Thus, the present study suggests that TRUSS is a novel substrate of E3 ligase Skp2 and that disruption of TRUSS-Skp2 interaction by viral oncoproteins could lead to pathophysiological sequelae.

Entities:  

Keywords:  E3 ubiquitin ligase; HBx; Skp2; TRUSS; c-Myc; cell cycle; ubiquitination

Mesh:

Substances:

Year:  2015        PMID: 26038816      PMCID: PMC4612110          DOI: 10.1080/15384101.2015.1056946

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  47 in total

Review 1.  The SCF ubiquitin ligase: insights into a molecular machine.

Authors:  Timothy Cardozo; Michele Pagano
Journal:  Nat Rev Mol Cell Biol       Date:  2004-09       Impact factor: 94.444

2.  Control of the SCF(Skp2-Cks1) ubiquitin ligase by the APC/C(Cdh1) ubiquitin ligase.

Authors:  Tarig Bashir; N Valerio Dorrello; Virginia Amador; Daniele Guardavaccaro; Michele Pagano
Journal:  Nature       Date:  2004-03-11       Impact factor: 49.962

3.  Cytosol is the prime compartment of hepatitis B virus X protein where it colocalizes with the proteasome.

Authors:  H Sirma; R Weil; O Rosmorduc; S Urban; A Israël; D Kremsdorf; C Bréchot
Journal:  Oncogene       Date:  1998-04-23       Impact factor: 9.867

4.  Hepatitis B virus X protein stimulates viral genome replication via a DDB1-dependent pathway distinct from that leading to cell death.

Authors:  Olivier Leupin; Séverine Bontron; Céline Schaeffer; Michel Strubin
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

5.  UV-induced ubiquitylation of XPC protein mediated by UV-DDB-ubiquitin ligase complex.

Authors:  Kaoru Sugasawa; Yuki Okuda; Masafumi Saijo; Ryotaro Nishi; Noriyuki Matsuda; Gilbert Chu; Toshio Mori; Shigenori Iwai; Keiji Tanaka; Kiyoji Tanaka; Fumio Hanaoka
Journal:  Cell       Date:  2005-05-06       Impact factor: 41.582

Review 6.  MYC oncogenes and human neoplastic disease.

Authors:  C E Nesbit; J M Tersak; E V Prochownik
Journal:  Oncogene       Date:  1999-05-13       Impact factor: 9.867

7.  A monoclonal antibody against the X protein of hepatitis B virus: fine mapping of its epitope and application in a quantitative ELISA of the X protein in sera of hepatitis B patients.

Authors:  V Kumar; N Jayasuryan; H Reddi; D Sahal; S K Panda
Journal:  Hybridoma       Date:  1998-04

8.  A truncated mutant (residues 58-140) of the hepatitis B virus X protein retains transactivation function.

Authors:  V Kumar; N Jayasuryan; R Kumar
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

9.  Human De-etiolated-1 regulates c-Jun by assembling a CUL4A ubiquitin ligase.

Authors:  Ingrid E Wertz; Karen M O'Rourke; Zemin Zhang; David Dornan; David Arnott; Raymond J Deshaies; Vishva M Dixit
Journal:  Science       Date:  2004-01-22       Impact factor: 47.728

10.  The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53.

Authors:  M Scheffner; J M Huibregtse; R D Vierstra; P M Howley
Journal:  Cell       Date:  1993-11-05       Impact factor: 41.582

View more
  11 in total

1.  Deubiquitinating c-Myc: USP36 steps up in the nucleolus.

Authors:  Xiao-Xin Sun; Rosalie C Sears; Mu-Shui Dai
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

2.  Skp2 is over-expressed in breast cancer and promotes breast cancer cell proliferation.

Authors:  Wenwen Zhang; Lulu Cao; Zijia Sun; Jing Xu; Lin Tang; Weiwei Chen; Jiayan Luo; Fang Yang; Yucai Wang; Xiaoxiang Guan
Journal:  Cell Cycle       Date:  2016-04-25       Impact factor: 4.534

Review 3.  Deregulation of F-box proteins and its consequence on cancer development, progression and metastasis.

Authors:  Jinho Heo; Rebeka Eki; Tarek Abbas
Journal:  Semin Cancer Biol       Date:  2015-09-30       Impact factor: 15.707

4.  TRIM58 suppresses the tumor growth in gastric cancer by inactivation of β-catenin signaling via ubiquitination.

Authors:  Xiaowen Liu; Ziwen Long; Hong Cai; Shengjia Yu; Jianghong Wu
Journal:  Cancer Biol Ther       Date:  2019-11-21       Impact factor: 4.742

Review 5.  MYC Modulation around the CDK2/p27/SKP2 Axis.

Authors:  Per Hydbring; Alina Castell; Lars-Gunnar Larsson
Journal:  Genes (Basel)       Date:  2017-06-30       Impact factor: 4.096

6.  Trans-ethnic predicted expression genome-wide association analysis identifies a gene for estrogen receptor-negative breast cancer.

Authors:  Guimin Gao; Brandon L Pierce; Olufunmilayo I Olopade; Hae Kyung Im; Dezheng Huo
Journal:  PLoS Genet       Date:  2017-09-28       Impact factor: 5.917

7.  Graft-Versus-Host Disease-Free Antitumoral Signature After Allogeneic Donor Lymphocyte Injection Identified by Proteomics and Systems Biology.

Authors:  Xiaowen Liu; Zongliang Yue; Yimou Cao; Sawa Ito; Jake Y Chen; Huanmei Wu; Sophie Paczesny; Lauren Taylor; Qing Zhang; Sung W Choi; Samir Hanash
Journal:  JCO Precis Oncol       Date:  2019-05-23

Review 8.  Targeting the MYC Ubiquitination-Proteasome Degradation Pathway for Cancer Therapy.

Authors:  Xiao-Xin Sun; Yanping Li; Rosalie C Sears; Mu-Shui Dai
Journal:  Front Oncol       Date:  2021-06-11       Impact factor: 6.244

9.  Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells.

Authors:  Ahmad Iskandarani; Ajaz A Bhat; Kodappully S Siveen; Kirti S Prabhu; Shilpa Kuttikrishnan; Muzammil A Khan; Roopesh Krishnankutty; Michal Kulinski; Rihab R Nasr; Ramzi M Mohammad; Shahab Uddin
Journal:  J Transl Med       Date:  2016-03-09       Impact factor: 5.531

Review 10.  Writing and erasing MYC ubiquitination and SUMOylation.

Authors:  Yingxiao Chen; Xiao-Xin Sun; Rosalie C Sears; Mu-Shui Dai
Journal:  Genes Dis       Date:  2019-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.